JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

Search

MannKind Corp

Closed

SectorHealthcare

3.82 -3.29

Overview

Share price change

24h

Current

Min

3.81

Max

4.06

Key metrics

By Trading Economics

Income

5.7M

13M

Sales

1.6M

78M

P/E

Sector Avg

38.2

38.156

Profit margin

16.793

Employees

403

EBITDA

8.3M

27M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+122.22% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-346M

1.2B

Previous open

7.11

Previous close

3.82

News Sentiment

By Acuity

50%

50%

157 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 Jul 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 Jul 2025, 23:54 UTC

Acquisitions, Mergers, Takeovers

EQT To Start Tender Offer for Fujitec

29 Jul 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 Jul 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 Jul 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 Jul 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 Jul 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 Jul 2025, 22:35 UTC

Earnings

IGO Maintains Nova Life of Mine Production Guidance

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 Jul 2025, 22:34 UTC

Market Talk
Earnings

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 Jul 2025, 22:33 UTC

Earnings

IGO Had A$279.7 Million of Cash at End-June

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Underlying Free Cash A$2.4 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO FY Sales Revenue A$512.5 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO FY Nickel Production 17,173 Tons

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 Jul 2025, 22:31 UTC

Earnings

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 Jul 2025, 22:31 UTC

Earnings

IGO FY Spodumene Production 1.48 Million Tons

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Underlying Ebitda A$62 Million

29 Jul 2025, 22:22 UTC

Earnings

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

122.22% upside

12 Months Forecast

Average 8.8 USD  122.22%

High 11 USD

Low 7 USD

Based on 5 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

157 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.